Company Filing History:
Years Active: 2016
Title: Melissa Geddie: Innovator in Bispecific Antibodies
Introduction
Melissa Geddie is a prominent inventor based in Somerville, MA (US). She has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies. Her innovative work has the potential to impact therapeutic approaches in various medical conditions.
Latest Patents
Melissa Geddie holds a patent for "ANTI-C-MET tandem Fc bispecific antibodies." This patent describes tandem Fcs and tandem Fc antibodies, known as TFcAs, which include one or more binding sites that specifically target cell surface receptors. The binding sites are interconnected through a TFc, which consists of a first and a second Fc region linked by a TFc linker to form a contiguous polypeptide. This innovative design allows for dimerization to create an Fc dimer. Notably, the exemplary TFcBAs developed by Geddie bind to the c-Met and EpCam receptors, effectively inhibiting signal transduction through these specific cell surface receptors.
Career Highlights
Melissa Geddie is currently associated with Merrimack Pharmaceuticals, Inc., where she continues to advance her research in the field of bispecific antibodies. Her work is characterized by a commitment to innovation and excellence in biotechnology.
Collaborations
Throughout her career, Melissa has collaborated with notable colleagues, including Brian Harms and Neeraj Kohli. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking therapeutic solutions.
Conclusion
Melissa Geddie's contributions to the field of bispecific antibodies exemplify her dedication to innovation in biotechnology. Her patent on ANTI-C-MET tandem Fc bispecific antibodies showcases her ability to create impactful solutions in medical science.